Anti-IFNA1/ IFL/ IFN functional antibody

Anti-IFNA1/ IFL/ IFN functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to IFNA1/IFNA1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0626-Ab-1/ GM-Tg-hg-SE0626-Ab-2Anti-Human IFNA1 monoclonal antibodyHuman
GM-Tg-rg-SE0626-Ab-1/ GM-Tg-rg-SE0626-Ab-2Anti-Rat IFNA1 monoclonal antibodyRat
GM-Tg-mg-SE0626-Ab-1/ GM-Tg-mg-SE0626-Ab-2Anti-Mouse IFNA1 monoclonal antibodyMouse
GM-Tg-cynog-SE0626-Ab-1/ GM-Tg-cynog-SE0626-Ab-2Anti-Cynomolgus/ Rhesus macaque IFNA1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0626-Ab-1/ GM-Tg-felg-SE0626-Ab-2Anti-Feline IFNA1 monoclonal antibodyFeline
GM-Tg-cang-SE0626-Ab-1/ GM-Tg-cang-SE0626-Ab-2Anti-Canine IFNA1 monoclonal antibodyCanine
GM-Tg-bovg-SE0626-Ab-1/ GM-Tg-bovg-SE0626-Ab-2Anti-Bovine IFNA1 monoclonal antibodyBovine
GM-Tg-equg-SE0626-Ab-1/ GM-Tg-equg-SE0626-Ab-2Anti-Equine IFNA1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0626-Ab-1/ GM-Tg-hg-SE0626-Ab-2; GM-Tg-rg-SE0626-Ab-1/ GM-Tg-rg-SE0626-Ab-2;
GM-Tg-mg-SE0626-Ab-1/ GM-Tg-mg-SE0626-Ab-2; GM-Tg-cynog-SE0626-Ab-1/ GM-Tg-cynog-SE0626-Ab-2;
GM-Tg-felg-SE0626-Ab-1/ GM-Tg-felg-SE0626-Ab-2; GM-Tg-cang-SE0626-Ab-1/ GM-Tg-cang-SE0626-Ab-2;
GM-Tg-bovg-SE0626-Ab-1/ GM-Tg-bovg-SE0626-Ab-2; GM-Tg-equg-SE0626-Ab-1/ GM-Tg-equg-SE0626-Ab-2
Products NameAnti-IFNA1 monoclonal antibody
Formatmab
Target NameIFNA1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IFNA1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-849Pre-Made Faralimomab Biosimilar, Whole Mab, Anti-Ifna1 Antibody: Anti-IFL/IFN/IFN-ALPHA/IFN-alphaD/IFNA13/leIF D therapeutic antibody
    BiosimilarGMP-Bios-INN-760Pre-Made Bifarcept Biosimilar, Recombinant Protein targeting IFNA1: Recombinant therapeutic protein targeting IFL/IFN/IFN-ALPHA/IFN-alphaD/IFNA13/leIF D
    BiosimilarGMP-Bios-ab-494Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody
    BiosimilarGMP-Bios-ab-519Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody
    Target AntigenGM-Tg-g-SE0626-Ag-1Recombinant multi-species IFNA1/ IFL/ IFN protein
    CytokineGM-Tg-g-SE0626-Ag-1interferon, alpha 1 (IFNA1) protein
    ORF Viral VectorvGMAP000481Human IFNA1 Adenovirus particle
    ORF Viral VectorvGMAD000576human IFNA1 Adenovirus particle
    ORF Viral VectorpGMAP000481Human IFNA1 Adenovirus plasmid
    ORF Viral VectorpGMLP000551human IFNA1 Lentivirus plasmid
    ORF Viral VectorvGMLP000551human IFNA1 Lentivirus particle
    ORF Viral VectorpGMAD000576human IFNA1 Adenovirus plasmid
    ORF Viral VectorpGMLPm000108mouse Ifna1 Lentivirus plasmid
    ORF Viral VectorvGMLPm000108mouse Ifna1 Lentivirus particle


    Target information

    Target IDGM-SE0626
    Target NameIFNA1
    Gene ID3439
    Gene Symbol and SynonymsIFL,IFN,IFN-ALPHA,IFN-alphaD,IFNA1,IFNA13,IFNA@,leIF D
    Uniprot AccessionN/A
    Uniprot Entry Name
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, INN Index, Cytokine Target
    Diseaseleukemia
    Gene EnsemblENSG00000197919
    Target ClassificationN/A

    The target: IFNA1, gene name: IFNA1, also named as IFL, IFN, IFN-ALPHA, IFN-alphaD3, IFNA@, IFNA1. This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. This cytokine is upregulated in preeclamptic placentas and is thought to be a mediator of preeclampsia. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.